Shanghai Pharmaceuticals Holding Co Ltd (601607) - Total Liabilities
Based on the latest financial reports, Shanghai Pharmaceuticals Holding Co Ltd (601607) has total liabilities worth CN¥143.90 Billion CNY (≈ $21.06 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Shanghai Pharmaceuticals Holding Co Ltd (601607) investment intensity to see how much of total assets are deployed in long-term investments.
Shanghai Pharmaceuticals Holding Co Ltd - Total Liabilities Trend (1994–2025)
This chart illustrates how Shanghai Pharmaceuticals Holding Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Shanghai Pharmaceuticals Holding Co Ltd.
Shanghai Pharmaceuticals Holding Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Pharmaceuticals Holding Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KION GROUP AG ADRS/1/4
F:KGX1
|
Germany | €12.55 Billion |
|
99 Speed Mart Retail Holdings Berhad
KLSE:5326
|
Malaysia | RM1.98 Billion |
|
Schaeffler India Limited
NSE:SCHAEFFLER
|
India | Rs23.65 Billion |
|
Bank of Maharashtra
NSE:MAHABANK
|
India | Rs3.94 Trillion |
|
CSN Mineração S.A
SA:CMIN3
|
Brazil | R$26.79 Billion |
|
Prestige Estates Projects Limited
NSE:PRESTIGE
|
India | Rs503.31 Billion |
|
JCHX Mining Management Co Ltd
SHG:603979
|
China | CN¥9.01 Billion |
|
Albertsons Companies
NYSE:ACI
|
USA | $24.59 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Shanghai Pharmaceuticals Holding Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 601607 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Pharmaceuticals Holding Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Pharmaceuticals Holding Co Ltd (1994–2025)
The table below shows the annual total liabilities of Shanghai Pharmaceuticals Holding Co Ltd from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥143.36 Billion ≈ $20.98 Billion |
+4.29% |
| 2024-12-31 | CN¥137.47 Billion ≈ $20.12 Billion |
+4.42% |
| 2023-12-31 | CN¥131.65 Billion ≈ $19.26 Billion |
+9.58% |
| 2022-12-31 | CN¥120.13 Billion ≈ $17.58 Billion |
+15.10% |
| 2021-12-31 | CN¥104.37 Billion ≈ $15.27 Billion |
+10.51% |
| 2020-12-31 | CN¥94.44 Billion ≈ $13.82 Billion |
+7.76% |
| 2019-12-31 | CN¥87.64 Billion ≈ $12.82 Billion |
+8.94% |
| 2018-12-31 | CN¥80.45 Billion ≈ $11.77 Billion |
+47.15% |
| 2017-12-31 | CN¥54.67 Billion ≈ $8.00 Billion |
+19.08% |
| 2016-12-31 | CN¥45.91 Billion ≈ $6.72 Billion |
+13.25% |
| 2015-12-31 | CN¥40.54 Billion ≈ $5.93 Billion |
+21.94% |
| 2014-12-31 | CN¥33.24 Billion ≈ $4.86 Billion |
+21.72% |
| 2013-12-31 | CN¥27.31 Billion ≈ $4.00 Billion |
+16.87% |
| 2012-12-31 | CN¥23.37 Billion ≈ $3.42 Billion |
+7.76% |
| 2011-12-31 | CN¥21.69 Billion ≈ $3.17 Billion |
+33.17% |
| 2010-12-31 | CN¥16.28 Billion ≈ $2.38 Billion |
+157.08% |
| 2009-12-31 | CN¥6.33 Billion ≈ $926.94 Million |
+11.80% |
| 2008-12-31 | CN¥5.67 Billion ≈ $829.08 Million |
+9.65% |
| 2007-12-31 | CN¥5.17 Billion ≈ $756.14 Million |
+12.05% |
| 2006-12-31 | CN¥4.61 Billion ≈ $674.83 Million |
+5.53% |
| 2005-12-31 | CN¥4.37 Billion ≈ $639.50 Million |
-0.75% |
| 2004-12-31 | CN¥4.40 Billion ≈ $644.31 Million |
+9.33% |
| 2003-12-31 | CN¥4.03 Billion ≈ $589.33 Million |
+18.34% |
| 2002-12-31 | CN¥3.40 Billion ≈ $498.00 Million |
+37.51% |
| 2001-12-31 | CN¥2.47 Billion ≈ $362.16 Million |
-2.94% |
| 2000-12-31 | CN¥2.55 Billion ≈ $373.14 Million |
+15.61% |
| 1999-12-31 | CN¥2.21 Billion ≈ $322.77 Million |
+16.23% |
| 1998-12-31 | CN¥1.90 Billion ≈ $277.71 Million |
+518.28% |
| 1997-12-31 | CN¥306.95 Million ≈ $44.92 Million |
-1.92% |
| 1996-12-31 | CN¥312.95 Million ≈ $45.79 Million |
+17.26% |
| 1995-12-31 | CN¥266.88 Million ≈ $39.05 Million |
+18.53% |
| 1994-12-31 | CN¥225.16 Million ≈ $32.95 Million |
-- |
About Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric … Read more